Cresset, innovative provider of computational software and services for small molecule drug discovery and design is joining the 3D-NEONET consortium of academics and SMEs. The consortium, which is funded through the EU’s Horizon 2020 programme, was created to enhance the sharing of technologies and the inter-disciplinary collaboration between companies and academics across Europe. The ultimate goal of the consortium being to accelerate the development of therapeutic interventions for oncology and ophthalmology.
A key element of the consortium’s work is to ensure that the next generation of researchers are skilled in advanced disciplines in order to advance the development of cancer and ophthalmic treatments. Cresset will provide training in computational chemistry techniques, and will provide access to software that will deliver important additional techniques enabling researchers to design and develop better drugs.
Dr Robert Scoffin, CEO of Cresset, said:
“This year, we’re delighted to welcome two PhD students from University College Dublin to Cresset for training in our computational chemistry software. The students will analyse protein targets, build homology models, run virtual screens and analyse the results. They will go on to apply these skills to address key challenges facing research and innovation today.”
Professor Breandán Kennedy, Principal Investigator at University College Dublin and 3D-NEONET Coordinator, said:
“With over 300 million people worldwide suffering vision impairment, and 10 million annual deaths from cancer, it’s essential that we embrace technologies to accelerate the development of new therapeutics. The 3D-NEONET consortium (Funded by H2020-RISE/GA734907) brings together a unique group of microbiologists, cancer biologists, chemists, material scientists, mechanical engineers, ocular pharmacologists, geneticists, toxicologists and computational chemists from 10 academic and 10 non-academic partner organisations in 7 countries.”
News & Analysis